{"entity":{"id":"nct03949283","kind":"trial","name":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","aka":[],"tldr":"A phase 3 trial of Standard Chemotherapy in ovarian cancer, run by Cordgenics, LLC, active and no longer recruiting.","summary":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer is a phase 3 interventional study registered as NCT03949283 by Cordgenics, LLC, with 150 participants enrolled, started 2019-07-26 and due to reach its primary completion in 2024-06-30. Interventions recorded: Standard Chemotherapy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03949283","url":"https://clinicaltrials.gov/study/NCT03949283"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03949283","phase":"3","setting":"Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","sponsor":"Cordgenics, LLC","enrolled":150,"outcomes":[]},"route":"/trials/nct03949283/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}]}}